Monday , December 18 2017
Home / KEEP BUT DO NOT DISPLAY / Alerts / Lixisenatide (Lyxumia) has been accepted for review by the FDA.

Lixisenatide (Lyxumia) has been accepted for review by the FDA.

Lixisenatide (Lyxumia) has been accepted for review by the FDA.

French drugmaker Sanofi said on Tuesday that its experimental GLP-1 once-daily diabetes drug lixisenatide (Lyxumia) has been accepted for review by the FDA. Sanofi is set to launch the drug in Europe shortly.